Zinger Key Points
- Shares of Zai Lab fall over 10% on Thursday.
- The stock has sold off sharply from strength seen on Tuesday.
- Get the Real Story Behind Every Major Earnings Report
Zai Lab Limited ZLAB shares traded lower on Thursday. The stock has pulled back sharply from recent strength. Here's what you need to know.
What To Know: Zai Lab stock has charged higher during December, especially in relation to the company's announcement last week regarding the addition of VYVGART, NUZYRA and ZEJULA to China's 2023 National Reimbursement Drug List.
While the stock was able to reach a three-month high on Tuesday, shares have since fallen sharply.
The more than 10% drop in price on Thursday was driven by abnormally high trading volume as well, with the stock experiencing above-average volume of 1.21 million shares, compared to its average volume of 427,978 shares.
Related Link: Oil Prices Fall After Angola Says It Will Quit OPEC
ZLAB Price Action: Shares of ZLAB were down 9.85% at $26.00 at the close of the market, according to Benzinga Pro.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.